WESTCHESTER COUNTY LIFE SCIENCES UPDATE

Westchester County Biosciences Accelerator Welcomes Boehringer Ingelheim, C3 Medical Device Consulting LLC and Moses Singer LLP as Corporate Supporters for 2023 Program

The Westchester County Biosciences Accelerator (WCBA), which supports the development of Westchester's hub of life science innovation and commercialization, is pleased to welcome three new corporate partners: Boehringer Ingelheim, C3 Medical Device Consulting LLC and

Moses Singer LLP.

Boehringer Ingelheim is one of the world’s leading research-driven pharmaceutical companies. C3 Medical Device Consulting LLC is a firm specializing in the development of next generation medical devices. Moses Singer LLP is a law firm with a health and technology practice that includes a specialization in cyber security for the medical field.



The Westchester County Office of Economic Development (WCOED) created the WCBA in 2019 to develop a pipeline of early-stage life sciences ventures and add to the more than 8,000 jobs and diverse variety of life science employers already located in Westchester and the New York metro region. Through the WCBA’s competitive-entry six-month program, founders receive coaching, network connections and business mentorship. The program includes a pitch competition where members of the cohort present their venture business plans. In addition to the WCBA program, the WCOED houses an Industry Desk identifying the trends and needs of the life science community, as well as a Task Force to discuss issues within the local and regional ecosystem.

Oligomerix Announces First-in-Human Dosing of

Tau Self-Association Inhibitor OLX-07010

White Plains-headquartered Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced the dosing of its first subjects in the company’s Phase 1a clinical trial evaluating lead candidate OLX-07010. This lead compound is a novel oral, small molecule inhibitor of tau self-association being assessed for the treatment of Alzheimer’s disease and other neurodegenerative disorders.



The objective of the Phase 1a study is to evaluate the safety and tolerability of OLX-07010 in single-ascending and multiple-ascending dose regimens in healthy volunteers, followed by the evaluation in a cohort of healthy elderly volunteers, the intended population.

Addressing women’s health care concerns with

Kistein Monkhouse, Founder & CEO, Patient Orator

Westchester County Bioscience Accelerator alum Kistein Monkhouse, founder and CEO of Patient Orator, a digital health startup that helps chronically ill and undeserved patients document their medical problems in a way that addresses mistrust between underrepresented communities and healthcare professionals, was a recent guest on

1A’s podcast series.

The podcast was dedicated to unpacking the reasons why gender and racial disparities exist in our healthcare system and creative solutions to the crisis. You can listen here.

Regeneron Announces Investor Conference Presentations

Tarrytown-headquartered Regeneron Pharmaceuticals, Inc. will webcast management participation as follows:

• SVB Securities Global Biopharma Conference at 9:20 a.m. ET: Tues., Feb. 14

• Cowen 43rd Annual Health Care Conference at 12:50 p.m. ET: Mon., March 6

• Oppenheimer 33rd Annual Healthcare Conference at 9:20 a.m. ET: Mon., March 13

• Barclays Global Healthcare Conference at 9:00 a.m. ET: Wed., March 15

The sessions may be accessed from the "Investors & Media" page of Regeneron's website. Replays of the webcasts will be archived on the Company's website for at least 30 days.

Have good news to share from

Westchester’s life sciences ecosystem?

Please let us know.

Email lifesciences@westchestergov.com.